tbc-11251 has been researched along with a 192621 in 1 studies
| Studies (tbc-11251) | Trials (tbc-11251) | Recent Studies (post-2010) (tbc-11251) | Studies (a 192621) | Trials (a 192621) | Recent Studies (post-2010) (a 192621) |
|---|---|---|---|---|---|
| 167 | 32 | 58 | 84 | 0 | 8 |
| Protein | Taxonomy | tbc-11251 (IC50) | a 192621 (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 0.0051 | |
| Endothelin-1 receptor | Homo sapiens (human) | 9.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duthie, KM; Hadoke, PW; Ivy, JR; Kirkby, NS; Lim, WG; McShane, JF; Miller, E; Webb, DJ | 1 |
1 other study(ies) available for tbc-11251 and a 192621
| Article | Year |
|---|---|
Selective endothelin A receptor antagonism with sitaxentan reduces neointimal lesion size in a mouse model of intraluminal injury.
Topics: Animals; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Femoral Artery; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Muscle Contraction; Muscle, Smooth, Vascular; Myography; Neointima; Pyrrolidines; Thiophenes | 2015 |